Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.
Kim ES, Park SK, Youn JC, Lee HS, Lee HY, Cho HJ, Choi JO, Jeon ES, Lee SE, Kim MS, Kim JJ, Hwang KK, Cho MC, Chae SC, Kang SM, Park JJ, Choi DJ, Yoo BS, Cho JY, Kim KH, Oh BH, Greenberg B, Baek SH.
Kim ES, et al. Among authors: lee hs, lee hy, lee se.
J Korean Med Sci. 2024 Jan 8;39(1):e8. doi: 10.3346/jkms.2024.39.e8.
J Korean Med Sci. 2024.
PMID: 38193327
Free PMC article.